IFC Holdings Incorporated FL purchased a new stake in shares of EXACT Sciences Co. (NASDAQ:EXAS) during the second quarter, according to its most recent filing with the SEC. The institutional investor purchased 28,813 shares of the medical research company’s stock, valued at approximately $1,017,000.

A number of other large investors have also made changes to their positions in EXAS. Rhumbline Advisers increased its stake in shares of EXACT Sciences by 1.2% in the second quarter. Rhumbline Advisers now owns 130,721 shares of the medical research company’s stock valued at $4,624,000 after buying an additional 1,511 shares in the last quarter. Smith Asset Management Group LP increased its stake in shares of EXACT Sciences by 23.9% in the second quarter. Smith Asset Management Group LP now owns 23,940 shares of the medical research company’s stock valued at $847,000 after buying an additional 4,620 shares in the last quarter. First Trust Advisors LP increased its stake in shares of EXACT Sciences by 111.5% in the second quarter. First Trust Advisors LP now owns 102,657 shares of the medical research company’s stock valued at $3,631,000 after buying an additional 54,121 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of EXACT Sciences by 5.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 511,041 shares of the medical research company’s stock valued at $18,076,000 after buying an additional 27,192 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its stake in shares of EXACT Sciences by 1,140.2% in the second quarter. Canada Pension Plan Investment Board now owns 475,000 shares of the medical research company’s stock valued at $16,801,000 after buying an additional 436,700 shares in the last quarter. 84.86% of the stock is currently owned by hedge funds and other institutional investors.

Shares of EXACT Sciences Co. (EXAS) opened at 37.76 on Friday. The firm’s 50-day moving average price is $37.62 and its 200 day moving average price is $28.82. EXACT Sciences Co. has a one year low of $13.05 and a one year high of $42.18. The company’s market capitalization is $4.50 billion.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.10. EXACT Sciences had a negative return on equity of 29.05% and a negative net margin of 53.41%. The firm had revenue of $57.65 million for the quarter, compared to analyst estimates of $47.73 million. Analysts anticipate that EXACT Sciences Co. will post ($1.18) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “IFC Holdings Incorporated FL Invests $1.02 Million in EXACT Sciences Co. (EXAS)” was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/13/ifc-holdings-incorporated-fl-invests-1-02-million-in-exact-sciences-co-exas.html.

EXAS has been the topic of several recent analyst reports. BidaskClub upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, June 22nd. Zacks Investment Research downgraded shares of EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, April 25th. Canaccord Genuity restated a “buy” rating and issued a $27.00 target price on shares of EXACT Sciences in a research note on Monday, April 24th. Vetr upgraded shares of EXACT Sciences from a “buy” rating to a “strong-buy” rating and set a $36.39 target price on the stock in a research note on Tuesday, June 13th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $25.00 target price on shares of EXACT Sciences in a research note on Wednesday, April 26th. Six research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. EXACT Sciences has a consensus rating of “Buy” and a consensus price target of $40.51.

In other news, SVP D Scott Coward sold 1,987 shares of EXACT Sciences stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $35.21, for a total transaction of $69,962.27. Following the sale, the senior vice president now directly owns 57,603 shares of the company’s stock, valued at $2,028,201.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jeffrey Thomas Elliott sold 5,846 shares of EXACT Sciences stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $39.41, for a total value of $230,390.86. Following the sale, the chief financial officer now directly owns 19,861 shares in the company, valued at $782,722.01. The disclosure for this sale can be found here. Company insiders own 4.00% of the company’s stock.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co. and related companies with MarketBeat.com's FREE daily email newsletter.